ALAS1 and hepatic porphyria: A small interfering RNA therapy targeting ALAS decreased plasma ALA and PBG levels in a mouse model of acute porphyria (Yasuda et al., 2014), and entered clinical trials in 2015 (Alnylam Pharmaceuticals, 2016, NCT02452372).